Evidence map›Paper›PMID 26332089›Full record

ReviewAnnual review of microbiology2015

Lytic Cycle of Toxoplasma gondii: 15 Years Later.

Ira J Blader, Bradley I Coleman, Chun-Ti Chen, Marc-Jan Gubbels

Open access · bronzeAbstract readReview
In one paragraph

Review in Annual review of microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 181 papers.

0numbers the graph read from it
0cells of the map it votes in
181citing papers in PubMed
11.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

181 citing papers in PubMed, 318 citations in OpenAlex.

  1. Antimicrobial agents and chemotherapy · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Genes · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. FEMS microbes · 2026
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

121 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Ira J BladerDepartment of Microbiology and Immunology, University at Buffalo, Buffalo, New York 14127; email: iblader@buffalo.edu.
Bradley I ColemanDepartment of Biology, Boston College, Chestnut Hill, Massachusetts 02467; email: bradley.coleman@bc.edu , chunti.chen@bc.edu , gubbelsj@bc.edu.
Chun-Ti ChenDepartment of Biology, Boston College, Chestnut Hill, Massachusetts 02467; email: bradley.coleman@bc.edu , chunti.chen@bc.edu , gubbelsj@bc.edu.
Marc-Jan GubbelsDepartment of Biology, Boston College, Chestnut Hill, Massachusetts 02467; email: bradley.coleman@bc.edu , chunti.chen@bc.edu , gubbelsj@bc.edu.
Boston College · USUniversity at Buffalo, State University of New York · US

Funding

CONTROL OF TOXOPLASMA GONDII GROWTH BY THE HOST CELL TRANSCRIPTION FACTOR HIF1R01AI069986 · NIAID · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI BLADER, IRA J · 2006 to 2021
$5.7M
Cytoskeleton scaffold assembly in Toxoplasma gondiiR01AI081924 · NIAID · BOSTON COLLEGE · PI GUBBELS, MARC-JAN · 2009 to 2012
$1.4M
Apicomplexan Drug Target DiscoveryR21AI107257 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI BLADER, IRA J · 2013 to 2014
$441k
Molecular and Informatics methods for whole-genome mutational profilingR21AI081220 · NIAID · BOSTON COLLEGE · PI GUBBELS, MARC-JAN, MARTH, GABOR T · 2009 to 2010
$430k
The role of the DOC2.1 protein in Toxoplasma gondii Ca2+- dependent exocytosisR21AI099658 · NIAID · BOSTON COLLEGE · PI GUBBELS, MARC-JAN · 2013 to 2014
$419k
Organization of Toxoplasma invasion and cell division by EF-hand proteinsR03AI107475 · NIAID · BOSTON COLLEGE · PI GUBBELS, MARC-JAN · 2013 to 2014
$157k
Molecular Discovery and Characterization within Toxoplasma Egress PathwaysF32AI108251 · NIAID · BOSTON COLLEGE · PI COLEMAN, BRADLEY IAN · 2014 to 2014
$55k
HSRD VA RRP 12-175NIAID NIH HHS F32 AI108251NIAID NIH HHS F32AI108251NIAID NIH HHS R01 AI069986NIAID NIH HHS R01AI069986NIAID NIH HHS R01 AI081924NIAID NIH HHS R01AI081924NIAID NIH HHS R03 AI107475NIAID NIH HHS R03AI107475NIAID NIH HHS R21 AI081220NIAID NIH HHS R21 AI099658NIAID NIH HHS R21AI099658NIAID NIH HHS R21 AI107257NIAID NIH HHS R21AI107257
6 · The paper itself

Abstract

Toxoplasmosis is the clinical and pathological consequence of acute infection with the obligate intracellular apicomplexan parasite Toxoplasma gondii. Symptoms result from tissue destruction that accompanies lytic parasite growth. This review updates current understanding of the host cell invasion, parasite replication, and eventual egress that constitute the lytic cycle, as well as the ways T. gondii manipulates host cells to ensure its survival. Since the publication of a previous iteration of this review 15 years ago, important advances have been made in our molecular understanding of parasite growth and mechanisms of host cell egress, and knowledge of the parasite's manipulation of the host has rapidly progressed. Here we cover molecular advances and current conceptual frameworks that include each of these topics, with an eye to what may be known 15 years from now.

Indexed as

AnimalsHost-Parasite InteractionsHumansProtozoan ProteinsToxoplasmaToxoplasmosisVacuolesProtozoan ProteinsApicomplexaegressendodyogenyinflammasomeinvasionIRG

Identifiers

PMID26332089
PMCPMC4659696
OpenAlexW2141592854

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.